CDKN2A and astrocytoma (excluding glioblastoma): Patients with astrocytoma and hemizygous <i>CDKN2A/B</i> deletion had shorter overall survival compared to patients with intact <i>CDKN2A/B</i> status (5.8 years vs 11.4 years, <i>P</i> = .04).